Label Changes for:
Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) Tablets
February 2008
Changes have been made to the BOXED WARNING, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- February 2008
| The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. |
| Sections Modified | Summary of Changes to Contraindications and Warnings |
|
BOXED WARNING WARNINGS
PRECAUTIONS
ADVERSE REACTIONS
PATIENT PACKAGE INSERT
|
BOXED WARNING ...Atripla is not approved for the treatment of chronic Hepatitis B Virus (HBV) infection and the safety and efficacy of Atripla have not been established in patients coinfected with HBV and HIV. Severe acute exacerbations of Hepatitis B have been reported in patients who have discontinued Emtriva or Viread which are components of Atripla... WARNINGS Patients Coinfected with HIV and HBV ...Severe acute exacerbations of Renal Impairment Emtricitabine and tenofovir are principally eliminated by the kidney, however efavirenz is not. Since Atripla is a combination product and the dose of the individual components cannot be altered, patients with creatinine clearance <50 mL/min should not receive Atripla. Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported in association with the use of tenofovir DF... It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy and as clinically appropriate during therapy with Atripla... |
